Ocular Genetic Studies in Achromatopsia

Achromatopsia is a rare autosomal recessive retinal disorder characterized by cone photoreceptor dysfunction. It typically presents from birth with symptoms such as photophobia, congenital nystagmus, poor visual acuity, and complete color blindness. Six genes—CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6—have been linked to achromatopsia. Among these, CNGA3 and CNGB3 mutations account for the majority of cases, particularly in Western populations. These mutations disrupt the cone phototransduction cascade, resulting in impaired cone function. Gene transfer via adeno-associated virus (AAV) vectors resulted in notable improvements in cone functioning in animal models with these alterations in preclinical investigations. Clinical trials have further supported these findings. Subretinal gene therapy applications using AAV vectors in patients with CNGA3 and CNGB3 mutations were proven to be safe and the patients showed notable improvements in their color vision, visual acuity, and ERG parameters. Early treatment appears to enhance therapeutic outcomes, particularly in younger patients. Long-term follow-up studies have confirmed the stability of cone function and the absence of severe adverse events, underlining gene therapy's promise for achromatopsia.